Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 803

Results For "ED"

10616 News Found

Atul Healthcare to acquire stake in VIMS
News | October 05, 2022

Atul Healthcare to acquire stake in VIMS

The agreement provides for acquisition of 13,50,000 equity shares of Rs. 100 each constituting 50% of the total equity share capital


Shionogi and MPP sign licence agreement for COVID-19 oral antiviral treatment
News | October 04, 2022

Shionogi and MPP sign licence agreement for COVID-19 oral antiviral treatment

Ensitrelvir is being evaluated for the treatment of COVID-19 to be administered as an oral tablet formulation taken once daily for five days.


Fluor bags award for Biologics manufacturing facility in Scandinavia
News | October 04, 2022

Fluor bags award for Biologics manufacturing facility in Scandinavia

Construction is now underway with the facility scheduled to be operational by 2025


Moderna creates new executive committee role for product launches
News | October 04, 2022

Moderna creates new executive committee role for product launches

Juan Andres Appointed to President, Strategic Partnerships and Enterprise Expansion


Lupin gets EIR from USFDA for its Ankleshwar facility
Drug Approval | October 03, 2022

Lupin gets EIR from USFDA for its Ankleshwar facility

The inspection of the facility was conducted from August 16-19, 2022.


SPARSH Hospitals, MGM Healthcare, Chennai to offer heart failure management program in Bengaluru
Healthcare | October 03, 2022

SPARSH Hospitals, MGM Healthcare, Chennai to offer heart failure management program in Bengaluru

This new initiative will cater to the increasing number of patients in Karnataka in need of heart and lung Failure management and transplant


Sumitovant Biopharma and Sumitomo Pharma to acquire outstanding shares of Myovant Sciences
News | October 03, 2022

Sumitovant Biopharma and Sumitomo Pharma to acquire outstanding shares of Myovant Sciences

The proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion.


Zydus receives final approval from the USFDA for Sildenafil for Oral Suspension
Drug Approval | October 01, 2022

Zydus receives final approval from the USFDA for Sildenafil for Oral Suspension

Sildenafil for Oral Suspension had annual sales of USD 65 million in the United States according to IQVIA data (IQVIA MAT Aug 2022).